Tonix Pharmaceuticals Highlights Preclinical Immuno-Oncology Data at AACR 2026 — Tonix Pharmaceuticals Holding Corp.

Event summary

Tonix Pharmaceuticals will present preclinical immuno-oncology data at the AACR Annual Meeting 2026, including one oral and two poster presentations.
The oral presentation focuses on TFF2 deficiency in gastric tumor progression, co-authored by Tonix executives Seth Lederman and Bruce Daugherty.
Poster presentations cover anti-BTLA monoclonal antibodies and pharmacokinetics of TNX-1700, both led by Bruce Daugherty.
TNX-1700, a fusion protein for gastric and colorectal cancer, is in pre-IND development stages.

The big picture

Tonix Pharmaceuticals is positioning itself as a player in both the central nervous system (CNS) and immuno-oncology markets. The AACR presentations highlight its preclinical efforts, particularly TNX-1700, which could diversify its revenue streams beyond existing CNS products like TONMYA and Zembrace Symtouch. The company's ability to leverage academic partnerships, such as with Columbia University, will be critical in advancing its immuno-oncology pipeline.

What we're watching

Clinical Development Pace: How quickly Tonix advances TNX-1700 from preclinical to IND stages will signal its ability to compete in the immuno-oncology space.
Data Validation: Whether the AACR presentation data translates into meaningful clinical outcomes for gastric and colorectal cancer treatments.
Strategic Focus: The balance Tonix maintains between its CNS commercial products and expanding immuno-oncology pipeline.